Ignite Creation Date:
2024-05-05 @ 11:23 AM
Last Modification Date:
2024-10-26 @ 9:06 AM
Study NCT ID:
NCT00015639
Status:
COMPLETED
Last Update Posted:
2008-03-04
First Post:
2001-04-25
Brief Title:
Identification of Donors of CD36-Deficient Platelets Among Japanese Individuals on the NIH Campus
Sponsor:
National Institutes of Health Clinical Center CC
Organization:
National Institutes of Health Clinical Center CC
Study Overview
Official Title:
Identification of Donors of CD36-Deficient Platelets Among Individuals on the NIH Campus
Status:
COMPLETED
Status Verified Date:
2004-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Plasma histidine-rich glycoprotein HRG binds to platelets in the presence of zinc 1 This binding is totally blocked by a monoclonal antibody directed against platelet membrane CD36 Therefore CD36 is assumed to carry the platelet binding site for HRG 2 Because CD36 also has a variety of other ligands including polyanionic lipids it is also possible that it contains the binding site for heparin also polyanionic and might be involve in the pathogenesis of heparin-induced thrombocytopenia Demonstrating absent HRG or heparin binding to platelets lacking CD36 would confirm that the binding sites for either or both of these ligands are located on this membrane protein Because 3 to 11 of healthy Japanese are reported to lack CD36 on their platelets this population is a practical source of cells for examining the physiologic roles for CD36 Therefore we will recruit blood donors from the Japanese community on the NIH campus Their platelets will tested for the presence of CD36 Recruitment will be closed after two individuals have been identified whose platelets lack CD36 and who are willing to donate 30 cc of blood on 4 or 5 subsequent occasions for binding studies with radiolabeled HRG and heparin
Detailed Description:
Plasma histidine-rich glycoprotein HRG binds to platelets in the presence of zinc 1 This binding is totally blocked by a monoclonal antibody directed against platelet membrane CD36 Therefore CD36 is assumed to carry the platelet binding site for HRG 2 Because CD36 also has a variety of other ligands including polyanionic lipids it is also possible that it contains the binding site for heparin also polyanionic and might be involved in the pathogenesis of heparin-induced thrombocytopenia Demonstrating absent HRG or heparin binding to platelets lacking CD36 would confirm that the binding sites for either or both of these ligands are located on this membrane protein Because 3 to 11 of healthy Japanese are reported to lack CD36 on their platelets this population is a practical source of cells for examining the physiologic roles for CD36 It has also been reported that 24 of African Americans and 4 of Taiwanese lack this protein on their platelets Therefore we will recruit blood donors from the Japanese African American and Taiwanese community on the NIH campus Their platelets will be tested for the presence of CD36 Recruitment will be closed after two individuals have been identified whose platelets lack CD36 and who are willing to donate 30 cc of blood on 4 or 5 subsequent occasions for binding studies with radiolabeled HRG and heparin
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 01-CC-0156 | None | None | None |